Menopausal Hot Flashes Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type (Oral Liquid v/s Pill), By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Competition 2020-2030F

Market Overview

Global Menopausal Hot Flashes Treatment Market was valued at USD 6.45 billion in 2024 and is expected to reach USD 8.79 billion by 2030 with a CAGR of 5.43% during the forecast period. The global menopausal hot flashes treatment market is evolving rapidly, driven by growing awareness of women's health issues and increasing demand for effective symptom management during menopause. As more women seek relief from the discomfort and disruption caused by hot flashes, the market is witnessing the introduction of a diverse range of treatment options. These include hormone replacement therapies, non-hormonal pharmaceuticals, herbal remedies, and lifestyle-oriented solutions such as dietary supplements and wellness programs.

Pharmaceutical companies are continuously investing in research and development to formulate therapies that are both effective and carry fewer side effects. For example, a December 2023 article in the Journal of the Menopause Society reported findings from an online study involving 12,268 postmenopausal women across countries like Brazil, Canada, Mexico, and several Nordic nations. It revealed that around 15.6% experienced moderate to severe vasomotor symptoms (VMS). This widespread prevalence is anticipated to fuel market growth in the coming years.  Hormone-based treatments remain widely used due to their proven efficacy, but concerns around long-term safety have led to a rising interest in non-hormonal alternatives. These alternatives are particularly appealing to women who are unable or unwilling to undergo hormone therapy, fueling innovation in selective serotonin reuptake inhibitors, plant-based treatments, and wearable cooling technologies. In addition to traditional treatment avenues, there is a notable shift toward personalized care and holistic wellness approaches. Healthcare providers are increasingly adopting integrated treatment plans that consider not only physical symptoms but also the emotional and psychological aspects of menopause. Telemedicine platforms and digital health tools are also playing a growing role in patient engagement, enabling better management and follow-up care.

The market is also being shaped by demographic and social changes, such as the growing population of aging women and the destigmatization of menopause in many regions. This cultural shift is empowering more women to seek professional medical help and demand high-quality treatments. As a result, the market is poised for continued growth, with opportunities emerging for both established players and new entrants offering innovative therapies that cater to the diverse and changing needs of menopausal women across the globe.

Key Market Drivers

Rising Awareness of Menopause-Related Health Issues

Rising awareness of menopause-related health issues has become a pivotal force driving the global menopausal hot flashes treatment market. For many years, menopause was considered a private or even taboo topic, leading to limited discussion and a lack of proactive medical engagement. However, in recent years, societal attitudes have shifted significantly. Health organizations, advocacy groups, and media platforms are increasingly highlighting the challenges women face during menopause, especially the disruptive symptoms such as hot flashes, night sweats, and sleep disturbances. This growing visibility has empowered women to seek medical advice and explore available treatment options more confidently. For example, in May 2023, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral treatment for moderate to severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. The introduction of such innovative therapies is likely to enhance access to menopausal treatments and support market growth in the coming years.

Educational initiatives and awareness campaigns are playing a critical role in informing women about the physiological changes associated with menopause and the importance of timely intervention. These efforts are not only helping women recognize symptoms earlier but also encouraging open dialogue with healthcare providers. As a result, there is a notable increase in consultations related to menopause management, leading to greater demand for both pharmaceutical and non-pharmaceutical solutions.

Healthcare professionals are also becoming more proactive in addressing menopausal symptoms during routine check-ups, further normalizing the conversation around menopause. At the same time, the digital era has enabled access to a vast pool of information, forums, and telemedicine services, making it easier for women to educate themselves and connect with specialists from the comfort of their homes.

The increased focus on women's health across global health agendas is also pushing policymakers and healthcare providers to prioritize menopause management. This has led to the development of specialized clinics, wellness programs, and tailored treatment regimens, all aimed at improving quality of life during this transition. In turn, this heightened awareness is translating into a larger, more engaged consumer base actively seeking effective solutions for hot flashes, thereby propelling the growth of the menopausal hot flashes treatment market.

Aging Female Population

The aging female population is a fundamental driver of growth in the global menopausal hot flashes treatment market. As life expectancy increases worldwide, a larger proportion of women are living well into their postmenopausal years, creating a substantial and expanding demographic in need of targeted healthcare solutions. Menopause typically occurs between the ages of 45 and 55, and with more women surviving beyond this age range, the demand for treatments that manage menopausal symptoms—particularly hot flashes—is steadily rising.

Hot flashes remain one of the most common and distressing symptoms of menopause, significantly impacting sleep, daily functioning, and overall quality of life. With a growing aging population, healthcare systems are witnessing a surge in consultations related to these symptoms, thereby increasing the uptake of both hormone and non-hormone-based treatments. This demographic trend is especially pronounced in developed nations, but it is also gaining importance in emerging economies where healthcare infrastructure is improving and awareness around menopause is increasing. The older women today are more informed, health-conscious, and proactive about managing age-related changes, leading to a more empowered consumer base that actively seeks out effective treatments. This shift in consumer behavior is encouraging pharmaceutical companies and wellness brands to develop and market therapies that are not only effective but also aligned with the preferences and health profiles of older women.

Governments and health organizations are also beginning to recognize the healthcare needs of this growing segment, leading to more research funding, policy initiatives, and supportive environments for innovation in menopausal care. Overall, the expanding aging female population represents a durable and growing demand base, offering significant opportunities for healthcare providers, pharmaceutical companies, and wellness product developers in the menopausal hot flashes treatment market.

Advancements in Drug Development

Advancements in drug development are significantly reshaping the landscape of the global menopausal hot flashes treatment market. Traditionally, hormone replacement therapy (HRT) has been the most widely used and effective treatment for hot flashes. However, concerns over the potential risks associated with long-term hormone use—such as cardiovascular complications and certain cancers—have spurred the pharmaceutical industry to invest heavily in the development of safer and more targeted alternatives. This shift has led to a surge in innovative therapies, particularly non-hormonal drugs, that aim to manage symptoms without the drawbacks of traditional hormone treatments. For example, in June 2023, Pfizer Inc. reintroduced DUAVEE (conjugated estrogens/bazedoxifene), an estrogen-based hormone therapy for menopause, back to the U.S. market. The relaunch followed a voluntary recall caused by packaging issues, which did not affect the product’s safety or effectiveness. The updated DUAVEE now comes with improved packaging.

One of the most promising developments in this space is the emergence of neurokinin receptor antagonists, which work by targeting the specific brain pathways responsible for regulating body temperature. These drugs offer a novel mechanism of action and have shown encouraging results in clinical trials for reducing both the frequency and severity of hot flashes. Their non-hormonal nature makes them especially suitable for women who cannot or choose not to take hormone-based treatments, thus expanding the therapeutic options available to a broader patient population.

In addition, drug developers are focusing on creating formulations that enhance patient adherence and comfort, such as extended-release tablets, transdermal patches, and non-invasive delivery systems. These innovations not only improve treatment effectiveness but also align with the growing demand for convenient, user-friendly solutions. Collaborations between research institutions, biotech firms, and pharmaceutical companies are accelerating the pace of discovery and regulatory approval. As a result, the treatment landscape is diversifying rapidly, offering safer and more personalized options to menopausal women globally. Ultimately, these advancements are increasing confidence in medical interventions for menopausal symptoms, driving higher treatment adoption and fueling the continued expansion of the global menopausal hot flashes treatment market.

Download Free Sample Report

Key Market Challenges

Safety Concerns Around Hormone Therapy

Safety concerns around hormone therapy remain one of the most significant challenges in the global menopausal hot flashes treatment market. While Hormone Replacement Therapy (HRT) has long been considered the most effective option for alleviating hot flashes and other vasomotor symptoms associated with menopause, its potential risks have created a climate of caution among both patients and healthcare providers. Studies linking long-term hormone use—particularly estrogen-progestin combinations—to increased risks of breast cancer, blood clots, stroke, and cardiovascular events have led to heightened scrutiny of HRT prescriptions.

These safety concerns have prompted regulatory authorities to issue strict guidelines on the use of hormone therapy, recommending the lowest effective dose for the shortest possible duration. As a result, many women and clinicians are either reluctant to initiate or continue HRT, particularly in cases where the patient has a personal or family history of hormone-sensitive conditions. This has limited the therapy’s appeal, despite its proven efficacy, and has created a significant demand for safer, non-hormonal alternatives. Moreover, the fear surrounding hormone therapy has contributed to misinformation and confusion, causing some women to avoid treatment altogether even when they might benefit from it. This underscores the need for clearer patient education and better risk-benefit communication by healthcare professionals.

These ongoing safety concerns are reshaping the treatment landscape, pushing pharmaceutical companies to innovate and develop non-hormonal therapies with better safety profiles. Addressing these concerns effectively is crucial for expanding patient access and building trust in the evolving options available for managing menopausal hot flashes.

High Cost of Treatment

The high cost of treatment presents a substantial barrier to the growth and accessibility of the global menopausal hot flashes treatment market. While effective therapies such as hormone replacement therapy (HRT), non-hormonal medications, and newer drug formulations are available, their affordability remains a concern for many women, particularly in low- and middle-income countries. Branded medications and advanced delivery systems, such as transdermal patches or extended-release formulations, often come at a premium price, limiting their adoption among cost-sensitive populations. In many regions, menopausal care is not prioritized within public healthcare systems, and treatments for hot flashes may not be covered by insurance or government programs. This forces many women to pay out-of-pocket, which can discourage them from seeking treatment altogether. Even in more developed markets, insurance reimbursement can be inconsistent, especially for newer or non-traditional therapies that may be classified as lifestyle or wellness-related rather than medically necessary.

The cost challenge also affects healthcare providers and systems, which may be hesitant to prescribe more expensive or experimental treatments without clear long-term cost-effectiveness data. As a result, the market faces a dual challenge: the need to ensure affordability while continuing to invest in innovative and safer therapeutic options. Addressing high treatment costs requires a multifaceted approach, including better insurance coverage, expanded access to generics, and supportive policy frameworks. Making affordable and effective treatments more widely available is essential for ensuring that a broader range of women—regardless of socioeconomic status—can benefit from advances in managing menopausal hot flashes.

Key Market Trends

Growing Preference for Non-Hormonal Therapies

The growing preference for non-hormonal therapies is emerging as a defining trend in the global menopausal hot flashes treatment market. Historically, hormone replacement therapy (HRT) has been the most widely used and effective option for managing vasomotor symptoms like hot flashes. However, concerns surrounding the long-term safety of HRT—including increased risks of breast cancer, stroke, and cardiovascular conditions—have led many women to seek alternative treatments. This shift in preference has opened the door for the development and adoption of non-hormonal therapies that offer relief without the potential complications associated with hormones.

Non-hormonal treatments encompass a wide range of options, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and clonidine. These medications, often prescribed off-label, have shown effectiveness in reducing hot flashes and night sweats. More recently, advancements in drug development have introduced targeted non-hormonal therapies such as neurokinin-3 (NK3) receptor antagonists, which directly act on brain pathways that regulate temperature, offering a novel mechanism of action for symptom relief. In addition to pharmaceuticals, there is increasing consumer interest in herbal supplements and plant-based remedies, such as black cohosh, soy isoflavones, and red clover. These options appeal to women looking for natural or integrative approaches, further broadening the spectrum of non-hormonal interventions. This trend is particularly important for women who are not eligible for HRT due to medical contraindications or personal choice. As healthcare providers become more aware of and confident in these alternatives, and as patients demand safer and more personalized options, the market for non-hormonal therapies is expected to expand significantly. The growing preference for such treatments underscores a broader movement toward risk-averse, patient-centric care and is reshaping the direction of innovation in the menopausal hot flashes treatment landscape.

Increased Use of Digital Health Platforms

The increased use of digital health platforms is transforming the global menopausal hot flashes treatment market by enhancing accessibility, personalization, and patient engagement. As menopause is a deeply personal and often stigmatized experience, many women appreciate the privacy and convenience that digital tools offer in managing their symptoms. Telemedicine services, mobile apps, and online health communities are becoming essential resources for women seeking guidance, support, and treatment options for hot flashes and other menopausal symptoms.

Telehealth platforms enable women to connect with healthcare providers remotely, eliminating geographical barriers and allowing for timely consultations. This is particularly valuable in regions where specialized menopausal care is scarce or where women may feel uncomfortable discussing sensitive symptoms face-to-face. Virtual appointments facilitate symptom assessment, treatment planning, and follow-up care with greater ease, helping women receive professional support without disrupting their daily routines. Mobile health apps further empower women by offering symptom tracking features, educational content, and personalized lifestyle recommendations. These tools allow users to monitor the frequency, intensity, and triggers of hot flashes, providing valuable data that can be shared with healthcare providers to tailor treatment plans more effectively. Some apps also integrate mindfulness exercises, dietary advice, and exercise regimens, supporting a holistic approach to menopause management.

Online communities and forums create spaces for peer support, where women can share experiences and coping strategies, reducing the sense of isolation often associated with menopause. This social engagement encourages more open conversations and greater awareness of available treatments. The rise of digital health platforms is making menopausal care more patient-centric, convenient, and data-driven. By bridging gaps in healthcare access and fostering continuous engagement, these technologies are accelerating treatment adoption and improving outcomes for women worldwide, thereby fueling growth and innovation in the menopausal hot flashes treatment market.

Segmental Insights

Type Insights

Based on type, oral pills currently dominate over oral liquid formulations. Pills are the preferred choice largely due to their convenience, ease of dosage, and widespread availability. They offer standardized dosing, longer shelf life, and simpler storage compared to liquid forms. This makes pills particularly appealing to both healthcare providers and patients for managing menopausal symptoms like hot flashes. On the other hand, oral liquids, while beneficial for patients who have difficulty swallowing pills or require flexible dosing, remain a niche segment. Liquids are less common in this market due to challenges such as shorter shelf life, the need for precise measuring devices, and potentially less convenience in everyday use.The most pharmaceutical innovations and clinical studies focus on solid oral dosage forms, reinforcing their dominance. As a result, oral pills continue to hold the majority market share, supported by patient familiarity, physician preference, and the logistical advantages of solid formulations. However, oral liquids may gradually gain traction as personalized and flexible treatment options grow in importance.

Treatment Type Insights

Based on treatment type, hormonal treatment remains the dominant segment, primarily because of its proven effectiveness in significantly reducing hot flashes and other menopausal symptoms. Hormone Replacement Therapy (HRT), which typically involves estrogen alone or combined with progestin, has been the gold standard for decades due to its ability to directly address the hormonal imbalances causing symptoms. Many healthcare providers continue to recommend HRT for women without contraindications, given its rapid symptom relief and extensive clinical backing. However, concerns about the potential risks of long-term hormone use—such as breast cancer, cardiovascular issues, and stroke—have created a growing demand for non-hormonal treatments. This segment is rapidly expanding as safer alternatives like neurokinin receptor antagonists, SSRIs, and herbal supplements gain popularity, especially among women who cannot or prefer not to use hormones. Alternative treatments such as lifestyle modifications, acupuncture, and herbal remedies also hold a smaller but growing share, mainly driven by increasing consumer interest in natural and holistic approaches. While hormonal treatments currently dominate due to their effectiveness and long history of use, non-hormonal options are rapidly gaining ground, reflecting evolving patient preferences and safety concerns.

Download Free Sample Report

Regional Insights

North America dominates the global menopausal hot flashes treatment market due to a combination of demographic, economic, and healthcare factors. The region has a large and aging female population, which significantly increases the demand for effective management of menopausal symptoms like hot flashes. With women living longer and reaching menopause in greater numbers, the need for treatment options is naturally higher. Healthcare infrastructure in North America is highly developed, featuring advanced medical facilities, well-established pharmaceutical industries, and widespread access to healthcare services. This facilitates early diagnosis and treatment of menopausal symptoms, boosting market growth. Moreover, there is strong awareness and acceptance of menopause-related health issues among both patients and healthcare providers, encouraging more women to seek treatment rather than endure symptoms silently. The region also benefits from robust research and development activities, with many pharmaceutical companies headquartered in North America investing heavily in developing innovative and safer therapies for menopausal symptoms. Regulatory frameworks are supportive of new drug approvals, enabling quicker market entry for novel treatments. The high disposable incomes and comprehensive insurance coverage make treatments more affordable and accessible to a larger segment of the population. All these factors combined make North America a leading market for menopausal hot flashes treatment, driving significant revenue and innovation in this space.

Recent Developments

• In August 2024, Bayer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elinzanetant, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. Elinzanetant is the first dual neurokinin-1 and 3 (NK-1 and NK-3) receptor antagonist in late-stage clinical development for this indication, administered orally once daily. The NDA submission is based on positive results from the Phase III OASIS 1, 2, and 3 studies, which demonstrated significant reductions in the frequency and severity of VMS compared to placebo, along with improvements in sleep disturbances and menopause-related quality of life.
• In October 2024, the FDA accepted Bayer's NDA for elinzanetant, marking a significant milestone in advancing menopause care for women in the U.S. The agency has set a Prescription Drug User Fee Act (PDUFA) target action date for July 26, 2025.
• In June 2023, Pfizer Inc. relaunched DUAVEE (conjugated estrogens/bazedoxifene), a hormone therapy for menopausal symptoms, in the United States. The relaunch followed a voluntary recall prompted by packaging issues, not by any concerns related to the product’s safety or efficacy. DUAVEE is used to treat moderate to severe hot flashes associated with menopause and to prevent postmenopausal osteoporosis. The return of the product to the market reinstates an important therapeutic option for women seeking estrogen-based treatment, especially those who cannot take progestins. Pfizer’s swift resolution of the packaging issue reflects its commitment to quality assurance and patient care.
• In December 2024, Health Canada approved Astellas Pharma’s Veozah, a non-hormonal treatment for moderate to severe vasomotor symptoms. This approval provides a new therapeutic option for managing hot flashes and night sweats linked to menopause, especially for women seeking alternatives to hormone therapy. Veozah marks a significant step forward in menopause care in Canada.

Key Market Players

• Abbvie, Inc.
• Allergan PLC.
• Bayer Ag.
• Cipla, Inc.
• Eli Lilly and Company.
• Emcure Pharmaceuticals Ltd.
• GSK PLC.
• Glenmark Pharmaceuticals Ltd.
• Hisamitsu Pharmaceutical Co. Inc.
• Merck & Co. Inc.

Report Scope:

In this report, the Global Menopausal Hot Flashes Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Menopausal Hot Flashes Treatment Market, By Type:

o   Oral

o   Liquid

o   Pill

• Menopausal Hot Flashes Treatment Market, By Treatment Type:

o   Hormonal Treatment

o   Non-Hormonal Treatment

o   Alternative Treatment    

• Menopausal Hot Flashes Treatment Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

• Menopausal Hot Flashes Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global •       Menopausal Hot Flashes Treatment Market.

Available Customizations:

Global Menopausal Hot Flashes Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).